PAROXETINE - PHARMACOKINETIC AND ANTIDEPRESSANT EFFECT IN THE ELDERLY
PAROXETINE - PHARMACOKINETIC AND ANTIDEPRESSANT EFFECT IN THE ELDERLY
复制标题
DOI：
10.1111/j.1600-0447.1989.tb07177.x
复制
发表时间：
1989-01-01
影响因子：
6.7
通讯作者：
WALINDER, J
中科院分区：
文献类型：
--
作者：
LUNDMARK, J;THOMSEN, IS;WALINDER, J
为了评估帕罗西汀在老年抑郁症患者中的药代动力学特性、疗效和耐受性，最初在丹麦的奥尔堡精神病医院开展了一项临床研究，随后在瑞典林雪平的大学医院开展。共有21例患者入组研究，中位年龄为72岁。在单次给予20或30 mg帕罗西汀后，随后两天停药，继续每天20或30 mg治疗7周。大多数患者的HAMD评分从治疗第二周开始持续下降。帕罗西汀在给药剂量下耐受性良好，副作用大多为轻度和一过性。帕罗西汀的稳态、给药前血浆水平显示出相当大的变异性，老年患者的中位稳态浓度高于先前在年轻志愿者中进行的研究的数据。这些老年患者之间的消除半衰期也存在差异，但停止多次给药后的消除半衰期往往长于单次给药后。他们也往往比年轻志愿者更长。这项研究的结果并不主张减少老年人帕罗西汀的剂量，但需要进一步的研究。
To evaluate the pharmacokinetic properties, efficacy, and tolerability of paroxetine in elderly depressed patients, a clinical study was set up ‐ initially at Aalborg Psychiatric Hospital in Denmark, and subsequently at the University Hospital in Linköping, Sweden. A total of 21 patients with a median age of 72 years were included in the study. After a single dose of 20 or 30mg of paroxetine followed by two drug‐free days, treatment continued with 20 or 30mg daily for seven weeks. The majority of patients showed a continuous reduction in their HAMD scores, starting in the second week of treatment. Paroxetine was well tolerated at the doses given, and side‐effects were mostly mild and transient. Steady‐state, pre‐dose plasma levels of paroxetine showed considerable variability, and the median steady‐state concentration was higher in elderly patients compared with data from a previous study in young volunteers. Elimination half‐lives also showed variability between these elderly patients, but tended to be longer after cessation of multiple dosing than after a single dose. They also tended to be longer than in the young volunteers. The results of this study do not advocate reduced doses of paroxetine in the elderly, but further studies are warranted.